Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3315 | Testing of SARS-CoV-2 antibodies Wiki | 0.38 |
drug3975 | questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality Wiki | 0.38 |
drug683 | Cannabis, Medical Wiki | 0.38 |
Name (Synonyms) | Correlation | |
---|---|---|
drug2283 | Online support Group Wiki | 0.38 |
drug1196 | Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2) Wiki | 0.38 |
drug3850 | life questionnaires Wiki | 0.38 |
drug782 | Co-mestring (co-coping) Wiki | 0.38 |
drug376 | BNT162b1 Wiki | 0.22 |
drug377 | BNT162b2 Wiki | 0.19 |
drug3976 | questionnaire Wiki | 0.13 |
drug2448 | Placebo Wiki | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
D012598 | Scoliosi NIH | 0.67 |
D000070627 | Chronic Traumatic Encephalopathy NIH | 0.38 |
D005879 | Tourette Syndrome NIH | 0.38 |
Name (Synonyms) | Correlation | |
---|---|---|
D009471 | Neuromyelitis Optica NIH | 0.38 |
D003424 | Crohn Disease NIH | 0.38 |
D005356 | Fibromyalgia NIH | 0.27 |
D000070642 | Brain Injuries, Traumatic NIH | 0.27 |
D000690 | Amyotrophic Lateral Sclerosis NIH | 0.27 |
D012640 | Seizures NIH | 0.27 |
D016472 | Motor Neuron Disease NIH | 0.27 |
D008269 | Macular Edema NIH | 0.27 |
D006526 | Hepatitis C NIH | 0.27 |
D001714 | Bipolar Disorder NIH | 0.27 |
D011111 | Polymyalgia Rheumatica NIH | 0.22 |
D013700 | Giant Cell Arteritis NIH | 0.22 |
D000755 | Anemia, Sickle Cell NIH | 0.19 |
D001930 | Brain Injuries, NIH | 0.17 |
D001927 | Brain Diseases NIH | 0.17 |
D002908 | Chronic Disease NIH | 0.17 |
D005221 | Fatigue NIH | 0.17 |
D010300 | Parkinsonian NIH | 0.15 |
D015212 | Inflammatory Bowel Diseases NIH | 0.14 |
D059350 | Chronic Pain NIH | 0.13 |
D004194 | Disease NIH | 0.08 |
D040921 | Stress Disorders, Traumatic NIH | 0.08 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.07 |
D014947 | Wounds and Injuries NIH | 0.07 |
D013577 | Syndrome NIH | 0.04 |
D003141 | Communicable Diseases NIH | 0.03 |
D007239 | Infection NIH | 0.02 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
D018352 | Coronavirus Infections NIH | 0.01 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100280 | Crohn's disease HPO | 0.38 |
HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.27 |
HP:0011505 | Cystoid macular edema HPO | 0.27 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100754 | Mania HPO | 0.27 |
HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.27 |
HP:0001250 | Seizure HPO | 0.22 |
HP:0012378 | Fatigue HPO | 0.17 |
HP:0001298 | Encephalopathy HPO | 0.17 |
HP:0002037 | Inflammation of the large intestine HPO | 0.14 |
HP:0012532 | Chronic pain HPO | 0.13 |
Navigate: Correlations HPO
There are 7 clinical trials
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsThe aim of the study is to understand the impact of COVID-19 on People with Multiple Sclerosis in the United Kingdom.
Description: Targeted questionnaire dependent on COVID Status
Measure: Incidence of COVID-19 Infections within an MS Cohort in the UK Time: Through study completion, an average of 1 yearDescription: Monitor admission rates in linked population
Measure: Hospitalisations in MS Patients with COVID-19 Time: 1 Year (regular outputs)Description: Death data from routinely reported government level data (HES/PEDW)
Measure: Mortality Time: 1 Year from study commencementDescription: Patient Reported Outcome for MS disability
Measure: Patient Reported Expanded Disability Status Score Time: 1 year (at least 6 monthly)Description: Patient Reported Outcome for anxiety and depression
Measure: Hospital Anxiety and Depression Scale Time: 1 year (at least 6 monthly)Description: Patient Reported Outcome for Multiple sclerosis impact on physical and psychological status
Measure: Multiple Sclerosis Impact Scale 29 V2 Time: 1 year (at least 6 monthly)Description: Patient Reported Outcome for walking status
Measure: Multiple Sclerosis Walking Scale 12 V2 Time: 1 year (at least 6 monthly)Description: Patient Reported Outcome for impact of fatigue
Measure: Fatigue Severity Scale Time: 1 year (at least 6 monthly)Description: Patient Reported Outcome for general quality of life
Measure: EuroQol 5D (3l) Time: 1 year (at least 6 monthly)The purpose of this study is to collect French medical data for patients with Multiple Sclerosis (MS) or NeuroMyelitis Optica (NMO) spectrum disorder who are diagnosed or strongly suspected of being infected with Covid19. The objective of this study is to provide scientific information regarding the possible risk factors in these patients, as a large part of them receive immunomodulatory or immunosuppressive treatments. The main objective of this study is thus to determine the epidemiological (eg, age, form of disease, disability) and pharmacological (related to immunomodulatory or immunosuppressive treatments) factors favoring the occurrence of a severe form of Covid-19 in MS and NMO patients.
Description: The main outcome measure is a clinical severity score on a 7-point severity scale at Nadir (in medicine, the most severe point in the progression of symptoms of a pathology). Nadir scale from 1 : Not hospitalized, no limitation of activities to 7 :Death
Measure: Clinical severity Time: 6 monthsDescription: EDSS is the Expanded Disability Severity Scale, a measure of neurological disability in patients with MS or NMO. EDSS Scale from 0: normal neurological examination to 10: MS-related Death
Measure: EDSS (Expanded Disability Status Scale) Time: 6 monthsStress and anxiety can have an adverse impact on health, and the experience of many around the 2020 outbreak of COVID-19 is affecting health and well-being. Individuals with chronic disease such as multiple sclerosis may be particularly vulnerable in some ways, but also particularly resilient in others. This study evaluates the effects of belonging to online support groups that meet weekly for 12 weeks to address the stress and anxiety felt by individuals with Multiple Sclerosis (MS). This study will also measure and explore the effects of online support groups.
Description: Acceptable rate is defined as at least 66% of participants who complete follow-up surveys.
Measure: Rate of completion Time: Up to 12 weeksDescription: Acceptable rate is defined as at least 66% of sessions being attended.
Measure: Rate of adherence Time: Up to 12 weeksDescription: The STAI is a commonly used measure of trait and state anxiety that is scored from 20 (minimum score) to 80 (maximum score), with a higher scores indicating higher anxiety (worse outcome).
Measure: Score on the State Trait Anxiety Inventory (STAI) Time: Up to 12 weeksDescription: Mood as measured by change in depression or depressive symptoms will be measured with the 8-item PHQ-8 which is scored from 0 (minimum score) to 24 (maximum score), in which higher scores indicate higher depression or depressive symptoms (worse outcome).
Measure: Score on the Personal Health Questionnaire Depression Scale (PHQ-8) Time: Up to 12 weeksThe containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation. Our hypothesis is that in patients with chronic diseases, confinement leads to changes in health behaviours, adherence to pharmacological treatment, lifestyle rules and increased psychosocial stress with an increased risk of deterioration in their health status in the short, medium and long term. Some messages about the additional risk/danger associated with taking certain drugs in the event of COVID disease have been widely disseminated in the media since March 17, 2020, the date on which containment began in France. This is the case, for example, for corticosteroids, non-steroidal anti-inflammatory drugs but also for converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor antagonists (ARBs2). These four major classes of drugs are widely prescribed in patients with chronic diseases, diseases specifically selected in our study (corticosteroids: haematological malignancies, multiple sclerosis, Horton's disease; ACE inhibitors/ARAs2: heart failure, chronic coronary artery disease). Aspirin used at low doses as an anti-platelet agent in coronary patients as a secondary prophylaxis after a myocardial infarction can be stopped by some patients who consider aspirin to be a non-steroidal anti-inflammatory drug. Discontinuation of this antiplatelet agent, which must be taken for life after an infarction, exposes the patient to a major risk of a new cardiovascular event. The current difficulty of access to care due to travel restrictions (a theoretical limit in the context of French confinement but a priori very real), the impossibility of consulting overloaded doctors, or the cancellation of medical appointments, medical and surgical procedures due to the reorganization of our hospital and private health system to better manage COVID-19 patients also increases the risk of worsening the health status of chronic patients who by definition require regular medical monitoring. Eight Burgundian cohorts of patients with chronic diseases (chronic coronary artery disease, heart failure, multiple sclerosis, Horton's disease, AMD, haemopathic malignancy, chronic respiratory failure (idiopathic fibrosis, PAH) haemophilia cohort) will study the health impact of the containment related to the COVID-19 pandemic.
Description: increase in dose, decrease in dose, discontinuation or no change for each drug class)
Measure: % adherence to each pharmacological class Time: during the period from 20 April 2020 to 7 May 2020Description: (mortality, hospitalizations and relevant criteria for each pathology all related to the chronic disease)
Measure: number of occurrence of medical events at 1 year Time: throughout the study for 12 monthsDescription: Smoking/Smoking/sweetening, Alcohol consumption/recovery, Decreased physical activity, Weight change
Measure: Expressed in %: Non-pharmacological treatment/lifestyle: Time: during the period from 20 April 2020 to 7 May 2020Hundreds of thousands of confirmed cases have been reported worldwide, just 3 months after the first patients were identified in Wuhan, China. Just like other members of the community, MS patients are uncomfortable with the emotional distress and health anxiety caused by the COVID-19 outbreak. Most MS patients receive immunosuppressive or immunomodulatory therapies. Patients taking immunosuppressive agents are theoretically at increased risk of being affected by viral pandemics, and a higher health concern is expected in this group of patients. Moreover, MS patients lose social support. Patients with increased duration of stay can no longer access physical and cognitive rehabilitation therapies. We also know that increased anxiety and sleep disorders can cause MS patients to have an attack. When literature is examined, it is known that MS patients' physical activity levels decrease, fatigue, sleep quality and anxiety levels increase, so their quality of life and participation in daily life activities decrease. MS patients lose social support during the COVID-19 outbreak. For all these reasons, we think that the fatigue, physical activity level, anxiety level and sleep disturbances affected before the COVID-19 outbreak will be further affected for these reasons.
Description: Fatigue was assessed by the Fatigue Severity Scale (FSS). This is a 9-item questionnaire that assesses the effect of fatigue on daily living. Each item is a statement on fatigue that the subject rates from 1 "completely disagree" to 7 "completely agree". A score of 4 or higher generally indicates severe fatigue
Measure: Fatigue Time: 4 weekDescription: Physical activity levels were assessed by the International Physical Activity Questionnaire (IPAQ): short form. The online self-reporting questionnaire consisted of questions investigating the respondents' PA practice in terms of frequencies and durations of sitting, walking, moderate-intensity physical activities and vigorous-intensity physical activities. The MET-minutes per week (MET-min/week) were calculated using the following formula: intensity (MET) x duration x frequency. Physical activity levels were classified as physically inactive (<600 MET-min/week), with low levels of physical activity (600-3000 MET- min/week) and physical activity level that is sufficient (> 3000 MET-min/week)
Measure: Physical activity Time: 4 weekDescription: The Pittsburgh Sleep Quality Index (PSQI) questionnaire was used to measure sleep quality using an 18-item scale containing seven items that included sleep quality, sleep duration, sleep latency, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. Each dimension scored between 0-3, with a total score ranging from 0-21, and a higher score indicating lower sleep quality.
Measure: Sleep quality Time: 4 weekDescription: The Hospital Anxiety and Depression Scale (HADS) was composed by two subscales (i.e., anxiety and depression), with 7-items each. The anxiety part of HADS was used to evaluate the anxiety levels of the patients. Each dimension scored between 0-3, with a total score ranging from 0-21, and a higher score indicating higher anxiety level.
Measure: Anxiety Time: 4 weekRationale: Patients with MS are possibly more vulnerable to infection with SARS-CoV-2. Furthermore the use of immunomodulatory treatment could have an effect on the course of COVID-19 disease. This has resulted in an alteration of current immunomodulatory treatment strategies and delaying the start of certain medications, which could induce MS disease activity. However, certain immunomodulatory treatments are also hypothesized to have a positive effect on COVID-19 disease. Besides lack of information regarding the effects of MS treatments on COVID-19, there is significant uncertainty in how we should advise MS patients in terms of self-isolation, resulting in many patients staying at home reluctant to perform their work or other daily activities. Nationally and locally, we are collecting information regarding COVID-19 in MS patients but numbers are low and only those who are severely affected are tested. Furthermore, there is no information regarding SARS-CoV-2 immunity in MS patients, which could be affected by certain MS treatments. Consequently, there is an urgent need for reliable information about infection rates/immunity and course of COVID-19 in relation to MS characteristics and treatments. Objectives: The objectives of this study are 1. to study the course of COVID-19 in MS patients in relation to immunomodulatory treatment and other patient and MS characteristics and 2. to study the proportion of MS patients with SARS-CoV-2 antibodies and 3. to establish the antibody profile in positive tested patients and 4. to study the longitudinal course of these antibody profiles in positive tested patients. Study design: This is a mono-center cohort study in patients of the MS Center Amsterdam. Study population: All patients with a diagnosis of MS currently under follow-up in the Amsterdam MS Center. Intervention (if applicable): Single venous puncture for drawing blood and questionnaire. For a minority of patients (max 25%) who test positive for antibodies we will draw blood a again with questionnaires after six and twelve months. Main study parameters/endpoints: Course of COVID-19 in MS patients in relation to MS immunomodulatory treatment.
Description: Correlationg of disease course of COVID-19 in patients with positive SARS-CoV-2 antibodies defined by questionnaires (asymptomatic, mild symptoms, severe symptoms, hospitalization) with MS immunomodulatory treatment (asked by questionnaires)
Measure: The correlation of COVID-19 disease course with MS immunomodulatory treatment Time: at baseline questionnaires and lab resultsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports